Abstract
AbstractMembers of the MEX3 (muscle excess 3) family, uniquely characterised as mRNA binding proteins, play emerging roles in the post-transcriptional regulation of programmed biological processes, including tumour cell death and immune mechanisms, and have been shown to be involved in a variety of diseases. However, the role of MEX3 in non-small cell lung cancer (NSCLC) has not been fully elucidated. In this study, we found no significant changes in the sequence and copy number of the MEX3 gene through analysis using the COSMIC database, revealing its stability during malignancy development. Its expression in NSCLC was examined using the Oncomine™ database, and the prognosis of each member gene was analysed by Kaplan–Meier. The results showed that overexpression of MEX3A, MEX3B, MEX3C and MEX3D was associated with significantly worse OS in patients with LUAD, while overexpression of MEX3D was also associated with significantly worse OS in patients with LUSC. Afterwards, we applied the Tumour Immunology Estimation Resource (TIMER) tool to assess the correlation between different MEX3 and infiltrative immune cell infiltration. Ultimately, we found that most MEX3 members were highly expressed in NSCLC, with high expression suggesting poor prognosis and correlating with immune cell infiltration. The complexity and heterogeneity of NSCLC was understood through MEX3, setting the framework for the prognostic impact of MEX3 in NSCLC patients and the development of new targeted therapeutic strategies in the future.
Funder
the Key Discipline of Jiaxing Respiratory Medicine Construction Project
Science Technology Project of Jiaxing
Jiaxing Key Laboratory of Precision Treatment for Lung Cancer
The Early Diagnosis and Comprehensive Treatment of Lung Cancer Innovation Team Building Project
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology
Reference51 articles.
1. Hentze, M. W., et al. (2018). A brave new world of RNA-binding proteins. Nature Reviews Molecular Cell Biology, 19(5), 327–341.
2. Pereira, B., Billaud, M., & Almeida, R. (2017). RNA-binding proteins in cancer: Old players and new actors. Trends Cancer, 3(7), 506–528.
3. Castello, A., et al. (2016). Comprehensive identification of RNA-binding domains in human cells. Molecular Cell, 63(4), 696–710.
4. Masuda, K., & Kuwano, Y. (2019). Diverse roles of RNA-binding proteins in cancer traits and their implications in gastrointestinal cancers. Wiley Interdisciplinary Reviews: RNA, 10(3), e1520.
5. Ceci, M., Fazi, F., & Romano, N. (2021). The role of RNA-binding and ribosomal proteins as specific RNA translation regulators in cellular differentiation and carcinogenesis. Biochimica et Biophysica Acta, Molecular Basis of Disease, 1867(4), 166046.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献